KRAS G12C inhibitors are a class of drugs designed to specifically target and inhibit the mutated KRAS G12C protein. These inhibitors bind to the cysteine residue in the mutant protein, locking it in an inactive state and preventing it from transmitting proliferative signals. This targeted approach aims to halt the growth of cancer cells driven by the KRAS G12C mutation.